Detection of Renal Malignancy of Complicated Renal Cysts

Status Completed

Clinical Trial Summary

The aim of this study was to show additional diagnostic criteria of computed tomography (CT) scan to diagnose and predict the detection and recurrence of cystic renal cell carcinoma in the patients with complicated renal cysts. Furthermore, we would demonstrate the relationship between complicated renal cysts diagnosed by Bosniak system and some parameters of pathological results. The analysis about detection time of renal malignancy would help determine the practical guidelines of follow-up plan for complicated renal cysts.

Clinical Trial Description

Even though there have been many trials and errors to enhance the diagnostic accuracy of CT scans for complicated cysts, the trial to obtain the enhanced accuracy using CT scan would be still valuable, when we consider its widespread use. A previous study demonstrated that the enhancement of HU with intravenous administration of contrast material on CT scan by 15 HU would be "almost always indicative of a pathologic process although not always a malignancy", another study showed the cut-off as 42 or 47 HU gap would be helpful in the prediction of renal malignancy. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01087060
Study type	Observational
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1997
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02248389` - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses	Phase 1
Completed	`NCT03900364` - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy	N/A
Completed	`NCT00158782` - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients	Phase 1
Completed	`NCT03109015` - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing	Phase 2
Completed	`NCT00363194` - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients	Phase 1
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT00842790` - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging	N/A
Completed	`NCT00529802` - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer	Phase 2
Completed	`NCT00387764` - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer	Phase 3
Completed	`NCT00356460` - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma	Phase 1
Completed	`NCT00338884` - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer	Phase 2
Completed	`NCT00095186` - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma	Phase 2
Completed	`NCT00043368` - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)	Phase 2
Completed	`NCT00079612` - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer	Phase 2
Active, not recruiting	`NCT04489771` - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)	Phase 2
Completed	`NCT00516672` - Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors	Phase 1
Withdrawn	`NCT05104905` - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT03111901` - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer	Phase 1/Phase 2
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1